Details

Autor(en) / Beteiligte

• Dampier, Carlton D.
• Telen, Marilyn Jo
• Wun, Ted
• Brown, R. Clark
• Desai, Payal
• El Rassi, Fuad
• Fuh, Beng
• Kanter, Julie
• Pastore, Yves
• Rothman, Jennifer
• Taylor, James G.
• Readett, David
• Sivamurthy, Krupa M.
• Tammara, Brinda
• Tseng, Li-Jung
• Lozier, Jay Nelson
• Thackray, Helen
• Magnani, John L.
• Hassell, Kathryn L.

Titel

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis

Ist Teil von

• Blood, 2023-01, Vol.141 (2), p.168-179

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• •Rivipansel was safe and well-tolerated in sickle cell patients hospitalized for VOC, but did not meet primary or secondary end points.•Rivipansel use early in the course of VOC appeared to shorten length of hospital stay and duration of IV opioid use in post-hoc analyses. [Display omitted] The efficacy and safety of rivipansel, a predominantly E-selectin antagonist, were studied in a phase 3, randomized, controlled trial for vaso-occlusive crisis (VOC) requiring hospitalization (RESET). A total of 345 subjects (204 adults and 141 children) were randomized and 320 were treated (162 with rivipansel, 158 with placebo) with an IV loading dose, followed by up to 14 additional 12-hourly maintenance doses of rivipansel or placebo, in addition to standard care. Rivipansel was similarly administered during subsequent VOCs in the Open-label Extension (OLE) study. In the full analysis population, the median time to readiness for discharge (TTRFD), the primary end point, was not different between rivipansel and placebo (−5.7 hours, P = .79; hazard ratio, 0.97), nor were differences seen in secondary end points of time to discharge (TTD), time to discontinuation of IV opioids (TTDIVO), and cumulative IV opioid use. Mean soluble E-selectin decreased 61% from baseline after the loading dose in the rivipansel group, while remaining unchanged in the placebo group. In a post hoc analysis, early rivipansel treatment within 26.4 hours of VOC pain onset (earliest quartile of time from VOC onset to treatment) reduced median TTRFD by 56.3 hours, reduced median TTD by 41.5 hours, and reduced median TTDIVO by 50.5 hours, compared with placebo (all P < .05). A similar subgroup analysis comparing OLE early-treatment with early-treatment RESET placebo showed a reduction in TTD of 23.1 hours (P = .062) and in TTDIVO of 30.1 hours (P = .087). Timing of rivipansel administration after pain onset may be critical to achieving accelerated resolution of acute VOC. Trial Registration: Clinicaltrials.gov, NCT02187003 (RESET), NCT02433158 (OLE). Dampier et al report on a large, randomized phase 3 clinical trial that compares the efficacy and safety of intravenous rivipansel, an E-Selectin antagonist, vs placebo in 345 adults and children admitted to the hospital for vaso-occlusive crises. The primary results show no significant reductions in duration of hospitalization or opioid use, while post-hoc analyses focusing on early use of rivipansel suggest some reductions in both.